Patents in Australia and New Zealand
Biotech Innovation Is Capital Intensive.
IP Mistakes Are Expensive.
Most small to mid-sized biotech companies operate without dedicated IP management. Strategic IP portfolio discipline often falls between roles.
-
Patent costs escalate with each jurisdiction and renewal cycle
-
Publication pressure risks novelty loss
-
University collaborations complicate inventorship
-
Investors scrutinise chain-of-title and freedom-to-operate
IP requires governance — not just filings.
Patents in Australia and New Zealand
Biotech innovation is capital-intensive, data-driven, and timeline sensitive.
Your IP strategy must be equally disciplined.
Most small to medium biotech companies face the same structural problem:
• No in-house IP manager
• Limited runway
• Complex collaborations
• Escalating patent costs
• Investor scrutiny of ownership and freedom-to-operate
Patent drafting alone is not strategy.
I provide independent, strategic IP advisory services designed specifically for Australian biotech SMEs — ensuring your patent portfolio supports valuation, commercialisation, and regulatory milestones without unnecessary cost escalation.
Protect What Drives Value
IP should strengthen valuation, accelerate investment, and support commercial success — not simply accumulate filings.
If you are building a biotech company and need disciplined, commercially aligned IP strategy, let’s discuss your portfolio.